Alicia Subasinghe

Alicia Subasinghe is an experienced professional in patient advocacy and strategic alliance development, currently serving as the Patient Advocacy Head at Cerevel Therapeutics since February 2021. Prior to this role, Alicia held the position of Director, Strategic Alliance Development at Novartis from June 2017 to February 2021. Alicia's extensive background also includes significant roles at PhRMA, where Alicia was the Senior Director of Alliance Development and Director of Policy & Research from November 2007 to June 2017. Earlier career experiences include serving as a Special Assistant at both the Office of Management and Budget and the Office of the United States Trade Representative in 2006, alongside roles at the National Republican Congressional Committee from January 2003 to January 2005. Alicia holds a Master of Arts in American Foreign Policy and International Economics from the Johns Hopkins School of Advanced International Studies (SAIS) and a Bachelor of Arts, cum laude, in Government and Politics with honors and Spanish Language and Literature from the University of Maryland.